February 24th 2023
Adult patients with chronic lymphocytic leukemia in the European Union can now receive treatment with acalabrutinib tablets.
January 19th 2023
December 14th 2022
Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLLJanuary 20th 2023
Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.
Mechanism of Action of BTK Inhibitors in Chronic Lymphocytic LeukemiaDecember 20th 2022
Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.
Zanubrutinib Produces Improved Survival Compared with Ibrutinib in Final PFS Analysis for Relapsed/Refractory CLLOctober 17th 2022
Topline results from the phase 3 ALPINE trial’s final progression-free survival analysis highlighted that zanubrutinib yielded higher progression-free survival compared with ibrutinib in patients with chronic lymphocytic leukemia.
Increased Atrial Fibrillation/Stroke Risk Did Not Impact TTD/TTNT Outcomes Associated with Ibrutinib for CLL/SLLOctober 3rd 2022
A real-world study found that time to discontinuation and time to next treatment outcomes associated with ibrutinib were not impacted by a baseline high risk of atrial fibrillation or stroke in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma.
Recap: Noninferiority Comparison of Acalabrutinib and Ibrutinib for Previously Treated CLLAugust 28th 2022
Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.
FDA Expresses Caution About Increased Risk of Death, Serious AEs Associated With Duvelisib in CLL/SLLJuly 11th 2022
The regulatory organization indicated that duvelisib induces increased risk of death or serious adverse effects in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
Venetoclax Plus Obinutuzumab Yield PFS Improvement in Untreated CLL, With or Without IbrutinibJune 16th 2022
Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.
Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to Obinutuzumab Plus Chemo in Treatment-Naïve CLLJune 4th 2022
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV StatusMay 18th 2022
Patients with untreated, IGHV-mutated and -unmutated chronic lymphocytic leukemia experienced better overall survival and progression-free survival with ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab.
Introduction and CLL BackgroundMay 16th 2022
Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.
First-Line Ibrutinib Discontinuation Due to Progression Significantly Higher in CLL With Vs Without Deletion 17pMay 11th 2022
Patients with treatment-naïve chronic lymphocytic leukemia with the presence of deletion 17p who received treatment with ibrutinib in the first line were more likely to have poor survival and to discontinue treatment due to progression vs those without.
Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL IndicationsApril 18th 2022
TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
Paul Barr, MD, Highlights Robust 8-Year Follow-Up Data of Frontline Ibrutinib in Older Patients With CLLApril 15th 2022
In an interview with CancerNetwork®, Paul Barr, MD, discusses 8-year follow-up data from the phase 3 RESONATE-2 trial, assessing first-line ibrutinib in patients 65 years of age or older with chronic lymphocytic leukemia.
Ibrutinib Plus Venetoclax at a Fixed Duration Yields Positive PFS in CLL/SLLApril 12th 2022
Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.
FDA Extends PDUFA Date for Ublituximab Plus Umbralisib BLA and sNDA in CLL/SLLMarch 3rd 2022
Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Analysis Uncovers Mechanisms of Resistance to BTK Inhibitors in R/R CLLMarch 2nd 2022
New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.
FDA Places Partial Clinical Hold on Studies Featuring Umbralisib and Ublituximab in CLL and Non-Hodgkin LymphomaFebruary 1st 2022
The FDA has placed a partial clinical hold on trials using umbralisib and ublituximab as a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.